Who makes [14c]-Samidorphan sublingual?

[14c]-Samidorphan sublingual is developed by Alkermes, Inc..

What development phase is [14c]-Samidorphan sublingual in?

[14c]-Samidorphan sublingual is in Phase 1.

Last reviewed 2026-04-19 · How we verify

[14c]-Samidorphan sublingual

Alkermes, Inc. · Phase 1 active Small molecule

At a glance

Generic name	[14c]-Samidorphan sublingual
Sponsor	Alkermes, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14c]-Samidorphan sublingual CI brief — competitive landscape report
[14c]-Samidorphan sublingual updates RSS · CI watch RSS
Alkermes, Inc. portfolio CI